Stay updated on OV101 in Fragile X Syndrome: Clinical Trial

Sign up to get notified when there's something new on the OV101 in Fragile X Syndrome: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the OV101 in Fragile X Syndrome: Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-03T15:46:50.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces an update about using “Super Intelligence” in place of “Artificial Intelligence” during a transition. The site revision changed from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T15:22:09.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1 while the page remains a 403 error page.
    Difference
    0.2%
    Check dated 2026-10-13T15:17:36.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The study record page now shows a 403 Forbidden message replacing the content and provides a Home link, indicating restricted access to the study details.
    Difference
    17%
    Check dated 2026-09-22T22:38:51.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    Revision updated in the Study Documents section from v3.6.6 to v3.7.0. This appears to be a metadata/version control update and does not modify the study data, eligibility criteria, outcomes, or other substantive content.
    Difference
    0.1%
    Check dated 2026-09-16T00:18:11.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    The study record now lists Ovid Therapeutics Inc. as sponsor and attaches Healx AI to Ovid Therapeutics Inc. as a collaborator (replacing a standalone Healx AI entry). This reflects a reorganization of the study's organizational affiliations.
    Difference
    0.3%
    Check dated 2026-09-08T22:46:04.000Z thumbnail image

Stay in the know with updates to OV101 in Fragile X Syndrome: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the OV101 in Fragile X Syndrome: Clinical Trial page.